PT  - JOURNAL ARTICLE
AU  - Sinclair, Heather Q.
ED  - Perlis, Roy
TI  - Therapeutic Augmentation for Treatment-Resistant MDD
DP  - 2009 Aug 01
TA  - MD Conference Express
PG  - 24--26
VI  - 9
IP  - 3
4099  - http://mdc.sagepub.com/content/9/3/24.short
4100  - http://mdc.sagepub.com/content/9/3/24.full
AB  - Major depressive disorder (MDD) affects about 15 million adults in the United States. Within that population, only one-third of patients who are treated with first-line antidepressant therapies achieve remission [Trivedi MH, Papakostas G, Perlis R. APA 2009]. Therefore, therapeutic augmentation, the addition of nonantidepressant compounds to an antidepressant regimen, may be a more reasonable option for those patients with first-line treatment resistance. This article explores the issue of treatment resistance in MDD and possible management strategies.